This phase 1 trial opened this month in New York, and will be opening in Virginia as well.
The vaccine is called VBI-1901 and consists of two CMV antigens (gB and pp65), delivered via enveloped virus-like particles (eVLP), plus GM-CSF as an adjuvant.
View trial outline here.
No comments:
Post a Comment